Financial Performance - For the year ended December 31, 2022, the Group's revenue decreased by approximately RMB797,000, or approximately 3.1%, from approximately RMB26.1 million in 2021 to approximately RMB25.3 million[37]. - Revenue from the male fertility IVD reagents segment was approximately RMB23.2 million for the year ended December 31, 2022, representing a decrease of approximately RMB151,000 or approximately 0.6% from approximately RMB23.3 million in 2021[38]. - Sales of healthcare products and supplements generated approximately RMB2.2 million for the year ended December 31, 2022, a decrease of approximately RMB646,000 or approximately 23.1% from approximately RMB2.8 million in 2021[39]. - The Group recorded a gross profit of approximately RMB16.9 million for the year ended December 31, 2022, an increase of approximately RMB458,000, or approximately 2.8%, from approximately RMB16.5 million in 2021[40]. - The gross profit margin increased from approximately 63.0% in 2021 to approximately 66.8% in 2022, mainly due to improved profit margins in the healthcare products and supplements segment[41]. - Healthcare products and supplements represented approximately 8.5% of the Group's total revenue for the year ended December 31, 2022, down from approximately 10.7% in 2021[31]. - Other income increased by approximately RMB 109,000 or about 14.1% to approximately RMB 884,000 for the year ended December 31, 2022, primarily due to an increase in interest income[45]. - The loss attributable to owners of the company decreased by approximately RMB 1.1 million or about 27.1% to approximately RMB 3.1 million for the year ended December 31, 2022, compared to approximately RMB 4.2 million for the year ended December 31, 2021[56]. Expenses and Costs - Selling and distribution expenses increased by approximately RMB 605,000 or about 7.2% to approximately RMB 9.0 million for the year ended December 31, 2022, primarily due to increased marketing activities during the epidemic[48]. - Administrative expenses rose by approximately RMB 450,000 or about 4.8% to approximately RMB 9.8 million for the year ended December 31, 2022, mainly due to increased staff costs[53]. - Research and development expenses remained stable, increasing slightly by approximately RMB 46,000 or about 1.9% to approximately RMB 2.5 million for the year ended December 31, 2022[54]. Cash and Equity - As of December 31, 2022, the group recorded total cash and bank balances of approximately RMB 33.3 million, a decrease from approximately RMB 36.2 million as of December 31, 2021, mainly due to payments of daily operating expenses[67]. - The equity attributable to owners of the Company amounted to approximately RMB 56.5 million as of December 31, 2022, down from approximately RMB 57.7 million in 2021[72]. - The Group's lease liabilities as of December 31, 2022, were approximately RMB 469,000, a decrease from approximately RMB 1.7 million in 2021[71]. Investments and Projects - In December 2022, the company entered an investment project for anoectochillus formosanus extractive (AFE), aiming to commercialize AFE products for the healthcare market[15]. - The Group plans to continue research on rapid Point-Of-Care diagnostic testing and intends to apply for medical device registration after satisfactory results[33]. - The Group aims to seek partners and distributors with sufficient sales channels and financial resources to promote the "Nutronic" brand more effectively[34]. Corporate Governance - The Company has adopted and complied with the Corporate Governance Code during the year ended December 31, 2022[176]. - The Board conducted reviews of the internal control system to ensure effectiveness and adequacy[177]. - The Company has a code of conduct regarding securities transactions that meets or exceeds the required standards[182]. - The Board is committed to high corporate governance standards to safeguard shareholder interests and enhance corporate value[175]. - The Company will continue to monitor and review its corporate governance practices[176]. Share Options and Capital Management - The Company adopted a Share Option Scheme to incentivise employees and assist in recruitment and retention of high-calibre personnel[108]. - A total of 26,008,000 share options were granted at an exercise price of HK$0.125 per share, with all options exercisable until April 8, 2030[113][114]. - The total number of share options as of December 31, 2022, is 23,504,000[116]. - The exercise price of the share options is HK$0.125, with a closing price of HK$0.125 immediately before the grant date[118]. - The expected life of the share options is ten years, with an expected volatility of 103.1%[119]. Management and Personnel - Mr. He is responsible for evaluating and developing new products related to male fertility and exploring overseas business cooperation opportunities[139]. - Dr. Chow has over 20 years of experience in biomedical testing and molecular diagnostics technology, leading commercialization efforts at Thunderbio[146]. - Dr. Cheng has over 25 years of experience in financial reporting, business advisory, auditing, and accounting[148]. - The financial controller and company secretary has over 17 years of experience in finance and accounting[163]. - The deputy general manager and chief technology officer has over 20 years of experience in the medical devices industry[166].
华康生物医学(08622) - 2022 - 年度财报